27 patents currently held
84 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
2 more records may belong here and await a decision; they are not counted.
The next term ends in Feb 2027. from the record
Of the 84 now held by other companies, 24 name Idorsia Pharmaceuticals Ltd. as their current owner, and 60 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
15
Ending by 2030
Feb 2027
Next term end
18
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Jun 2030 · High confidence
Also notable
Ends Apr 2030 · High confidence
Also notable
Ends Apr 2029 · High confidence
Therapeutic Compositions Containing Macitentan
US 8,809,334
The most cited patent in this portfolio, cited by 70 later US patents, top 10% of utility patents granted in 2014 in our data. Protection runs to 2030.
Dosing Regimen for a Selective S1P1 Agonist
US 10,660,880
Cited by 15 later US patents, top 25% of utility patents granted in 2020 in our data. Protection runs to 2030.
Therapeutic Compositions Comprising a Specific Endothelin Receptor Antagonist and a PDE5 Inhibitor
US 8,268,847
The largest patent family in this portfolio, 9 related applications, renewed at 3 of 3 maintenance windows. Protection runs to 2029.
Formerly held, still cited
Notable
Ends Jul 2029 · High confidence
The most cited patent in this portfolio, cited by 73 later US patents, top 10% of utility patents granted in 2011 in our data. Protection runs to 2029.
now held by Helsinn Birex Pharmaceuticals Limited
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due May 3, 2027The maintenance fee for Therapeutic Compositions Containing Macitentan (US 9,173,881) comes due May 3, 2027. Unpaid by Nov 3, 2027, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 17, 2026
- 3 terms have ended since Aug 17, 2026
What they patent
The 5 largest of its 18 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Dosing Regimen for a Selective S1P1 Receptor Agonist | 3 in force | to Jun 2030 |
| Therapeutic Compositions Containing Macitentan | 3 in force | to Jun 2030 |
| Stable Pharmaceutical Compositions Comprising a Pyrimidine-Sulfamide | 3 in force | to Oct 2028 |
| Pharmaceutical Composition For The Treatment Of Pulmonary Arterial Hypertension | 2 in force | to Dec 2039 |
| Preparation of Pyrimidine Intermediates Useful for the Manufacture of Macitentan | 2 in force | to Mar 2034 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,598,227 | Novel Epoprostenol Formulation and Method of Making Thereof In force · High confidence | In force | High confidence | |
| US 11,648,249 | Stable Pharmaceutical Compositions Comprising a Pyrimidine-Sulfamide In force · Medium confidence | In force | Medium confidence | |
| US 8,318,802 | Novel Epoprostenol Formulation and Method of Making Thereof In force · High confidence | In force | High confidence | |
| US 9,265,762 | Stable Pharmaceutical Compositions Comprising a Pyrimidine-Sulfamide In force · High confidence | In force | High confidence | |
| US 7,959,945 | Dispersible Bosentan Tablet In force · High confidence | In force | High confidence | |
| US 7,868,012 | Sulfamides as Endothelin Receptor Antagonists for the Treatment of Cardiovascular Diseases In force · High confidence | In force | High confidence | |
| US 8,124,623 | 5-Hydroxymethyl-OXAZOLIDIN-2-ONE-DERIVATIVES and Their Uses as Antibacterials In force · High confidence | In force | High confidence | |
| US 8,367,685 | Stable Pharmaceutical Compositions Comprising a Pyrimidine-Sulfamide In force · High confidence | In force | High confidence | |
| US 8,268,847 | Therapeutic Compositions Comprising a Specific Endothelin Receptor Antagonist and a PDE5 Inhibitor In force · High confidence | In force | High confidence | |
| US 9,173,881 | Therapeutic Compositions Containing Macitentan In force · High confidence | In force | High confidence |
Also on record, not counted in the 27: 84 patents in force now held by others · 168 patents ended · 6 applications pending · 93 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.